Neoadjuvant ICI with therapeutic antibodies such as those targeting PD-1 has shown promise toward mitigating recurrence and improving outcomes in advanced resectable melanoma, mismatch-repair deficient colon cancer and other cancer indications (10, 11). The gene discussed is PDCD1; the disease is cancer.